A CRISPR::Cr-P300M crotonylation modification editing tool and its application

The CRISPR::Cr-P300M tool is used to modify gene site-directed crotonylating in mammalian cells, which solves the problem of lack of site-directed editing tools in the prior art, and improves gene expression and myotubule differentiation of mammalian cells.

CN118291415BActive Publication Date: 2024-11-19INNER MONGOLIA UNIVERSITY
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410291699.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-14
Publication Date
2024-11-19
Estimated Expiration
2044-03-14

AI Technical Summary

Technical Problem

The prior art lacks the establishment and related applications of a gene-directed crotonylation modification editing tool, especially in promoting gene transcription and myotubule differentiation in mammalian cells.

Method used

A CRISPR::Cr-P300M gene site-directed crotonylation modification tool was developed to achieve accurate transcriptional initiation sites of myogenesis marker genes MYOG and MYMK by fusing fusion proteins of dCas9 and P300 mutants, as well as specific sgRNAs. Crotonylation modification promotes gene expression and myotubule differentiation.

Benefits of technology

It effectively improves gene expression level and myotubes differentiation ability, provides a new method of gene epithelial modification and editing, and provides new ideas for gene editing animals.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118291415B_ABST
    Figure CN118291415B_ABST
Patent Text Reader

Abstract

The present invention relates to a CRISPR::Cr-P300M crotonylation modification editing tool and its application. The crotonylation modification editing tool comprises: a fusion protein of dCas9 and a P300 mutant and sgRNA, the amino acid sequence of the P300 mutant is shown in SEQ ID NO: 2, the sgRNA targets the transcription start site of MYMK, and the nucleotide sequence of the sgRNA is: sg-MYMK-Bos is shown in SEQ ID NO: 4; sg-MYMK-Mus is shown in SEQ ID NO: 6. The tool promotes transcription and translation by increasing the crotonylation modification of the target gene, can upregulate gene expression and promote myotube differentiation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of gene editing technology, and in particular to the preparation and application of a CRISPR::Cr-P300M crotonylation modification editing tool. Background Art

[0002] Lysine crotonylation (Kcr) refers to a modification produced by histone crotonyltransferase (HCT) using crotonyl coenzyme A (Cr-CoA) as a substrate to transfer crotonyl groups to lysine residues. Similar to most acylation modifications, Kcr requires the participation of writers, readers, and erasers, among which E1A binding protein p300 (P300) plays a major role in the modification of crotonyltransferases in mammalian cells.

[0003] P300 can catalyze acetylation and crotonylation at the same time. Further studies have found that after the isoleucine responsible for the acetylation modification activity of the P300 protein is mutated to glycine, the P300 mutant loses the function of catalyzing acetylation but retains the initiation of crotonylation modification. In in vitro transcription-related experiments, after the P300 mutant replaced the endogenous P300, the transcription level of the gene was significantly improved. However, the current progress lacks the establishment of a gene-specific crotonylation modification editing tool and its related applications. Summary of the invention

[0004] In order to achieve the purpose of the present invention, in a first aspect, the present invention provides a P300 mutant, the amino acid sequence of the mutant is shown in SEQ ID NO:1.

[0005] Preferably, the mutant is obtained by mutating isoleucine at position 1395 of P300 to glycine, and the amino acid sequence of P300 is shown in SEQ ID NO:1.

[0006] In a second aspect, the present invention provides a composition for site-directed crotonylation modification of the CRISPR::Cr-P300M gene, comprising: a fusion protein of dCas9 and a P300 mutant, and sgRNA.

[0007] Preferably, the amino acid sequence of the P300 mutant is as shown in SEQ ID NO:2.

[0008] Preferably, the dCas9 and P300 mutant are fused directly or via a connecting peptide.

[0009] Preferably, the connecting peptide is P2A.

[0010] Preferably, the sgRNA targets the transcription start sites of the myogenic marker genes MYOG and MYMK, and the myogenic marker genes MYOG and MYMK are of bovine or mouse origin.

[0011] Preferably, the nucleotide sequence of the sgRNA is:

[0012] sg-MYOG-Bos is shown in SEQ ID NO: 3;

[0013] sg-MYMK-Bos is shown in SEQ ID NO: 4;

[0014] sg-MYOG-Mus is shown in SEQ ID NO: 5;

[0015] sg-MYMK-Mus is shown as SEQ ID NO:6.

[0016] In a preferred embodiment of the present invention, a CRISPR::Cr-P300M gene site-directed crotonylation modification editing vector is provided, comprising an sgRNA expression cassette and a dCas9 and P300 mutant fusion protein expression cassette.

[0017] Wherein, the amino acid sequence of the P300 mutant is shown in SEQ ID NO: 1, the sgRNA targets the transcription start sites of bovine myogenic marker genes MYOG and MYMK, or the sgRNA targets the transcription start sites of mouse myogenic marker genes MYOG and MYMK.

[0018] In a third aspect, the present invention provides a P300 mutant, a composition for site-directed crotonylation modification of the CRISPR::Cr-P300M gene, or an editing vector for site-directed crotonylation modification of the CRISPR::Cr-P300M gene in a site-directed crotonylation modified cell.

[0019] In a fourth aspect, the present invention provides a method for preparing gene-site-directed crotonylation-modified cells, comprising introducing a CRISPR::Cr-P300M gene-site-directed crotonylation-modified composition or a CRISPR::Cr-P300M gene-site-directed crotonylation-modified editing vector into target cells to obtain gene-site-directed crotonylation-modified cells.

[0020] Preferably, the target cells include bovine muscle satellite cells or mouse C2C12 myoblasts.

[0021] Preferably, the bovine muscle satellite cells are bovine fetal muscle satellite cells.

[0022] Preferably, the introduction method comprises liposome transfection or electroporation.

[0023] Preferably, the introduction method is liposome transfection.

[0024] The edited cell screening method is to separate edited single cells by limiting dilution method for culture.

[0025] The identification method is ChiP-qPCR of crotonylated pan-antibody.

[0026] By means of the above technical solution, the present invention has at least the following advantages and beneficial effects:

[0027] The present invention provides a tool for site-directed crotonylation modification editing of mammalian genes. The tool vector can express sgRNA and dCas9 and P300M fusion protein, and promote transcription and translation by increasing the crotonylation modification of the target gene. Taking BMSC and C2C12 cells as examples, the transcription start sites of the myogenic marker genes MYOG and MYMK are respectively subjected to site-directed crotonylation modification editing, which can upregulate gene expression and promote myotube differentiation. The invention of the gene site-directed crotonylation modification system broadens the way of gene epigenetic modification editing and provides a new idea for the breeding of gene-edited animals.

[0028] The concept, specific structure and technical effects of the present invention will be further described below in conjunction with the accompanying drawings to fully understand the purpose, characteristics and effects of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 The amino acid sequences of bovine and mouse core P300 proteins and a schematic diagram of bovine P300 mutants are shown.

[0030] Figure 2 Editing plasmid map for CRISPR::Cr-P300M crotonylation modification.

[0031] Figure 3 These are sgRNA sequences targeting the transcription start sites of bovine myogenic marker genes MYOG and MYMK, as well as sgRNA sequences targeting the transcription start sites of mouse myogenic marker genes MYOG and MYMK.

[0032] Figure 4 The effect of CRISPR::Cr-P300M plasmid transfection on the viability of bovine muscle satellite cells (BMSCs) and mouse C2C12 myoblasts.

[0033] Figure 5ChiP-qPCR was used to detect the intensity of crotonylation modification at the transcription start sites of bovine and mouse myogenic marker genes MYOG and MYMK in order to perform site-specific crotonylation editing on the transcription start sites of bovine muscle satellite cells (BMSCs) and mouse C2C12 myoblasts, respectively.

[0034] Figure 6 ChiP-qPCR was used to detect the intensity of acetylation modification at the transcription start sites of bovine and mouse myogenic marker genes MYOG and MYMK in order to perform site-specific crotonylation editing on the transcription start sites of bovine muscle satellite cells (BMSCs) and mouse C2C12 myoblasts, respectively.

[0035] Figure 7 In order to perform site-specific crotonylation editing on the transcription start sites of bovine muscle satellite cells (BMSCs) and mouse C2C12 myoblasts, the transcription levels of bovine and mouse myogenic marker genes MYOG and MYMK after site-specific crotonylation editing were detected by fluorescence quantitative PCR.

[0036] Figure 8 In order to perform site-specific crotonylation editing on the transcription start sites of bovine muscle satellite cells (BMSCs), the translation levels of bovine myogenic marker genes MYOG and MYMK after site-specific crotonylation editing were detected by Western blotting.

[0037] Fig. 9 In order to perform site-specific crotonylation editing on the transcription start sites of mouse myogenic marker genes MYOG and MYMK in mouse C2C12 myoblasts, Western blotting was used to detect the translation levels of mouse myogenic marker genes MYOG and MYMK after site-specific crotonylation editing.

[0038] Fig.10 To perform site-specific crotonylation editing on the transcription start sites of bovine muscle satellite cells (BMSCs), and to detect the myotube formation after site-specific crotonylation editing of bovine myogenic marker genes MYOG and MYMK.

[0039] Fig.11 To perform site-specific crotonylation editing on the transcription start sites of the myogenic marker genes MYOG and MYMK in mouse C2C12 myoblasts, and to detect the myotube formation after site-specific crotonylation editing of the mouse myogenic marker genes MYOG and MYMK. DETAILED DESCRIPTION

[0040] The following describes several preferred embodiments of the present invention with reference to the drawings in the specification, so that the technical content is clearer and easier to understand. The present invention can be embodied in many different forms of embodiments, and the protection scope of the present invention is not limited to the embodiments mentioned in the text; in the figure: Muc is the abbreviation of mouse; Bos is the abbreviation of cattle; WT (wild-type) is wild type; M (mutant) is mutant.

[0041] The present invention provides a CRISPR::Cr-P300M crotonylation modification editing tool, wherein the tool vector contains an sgRNA expression cassette, and a dCas9 and P300 mutant fusion protein expression cassette.

[0042] In the above system, sgRNA can target the region near the gene transcription start site, dCas9 protein binds to the target sequence but does not cut, and P300 mutant protein can increase the gene crotonylation modification level but does not affect acetylation modification.

[0043] It should be noted that sgRNA can achieve the transcription start site of the targeted gene, and there is no restriction on the specific sequence, as long as it can achieve precise targeting function. dCas9 protein can bind to but not cut DNA in a variety of cells, and has the advantages of wide application range and high binding efficiency. P300 mutant protein will promote the crotonylation modification level of the binding site, but will not affect its acetylation level.

[0044] In a preferred embodiment, the nucleotide sequence of the sgRNA targeting the transcription start site of the bovine myogenic marker genes MYOG and MYMK, and the nucleotide sequence of the sgRNA targeting the transcription start site of the mouse myogenic marker genes MYOG and MYMK are shown in SEQ ID NOs: 3, 4, 5 and 6. MYOG (myogenin) is a member of the myogenic regulatory factor family, MYMK (myomaker) is located in the plasma membrane and participates in myoblast fusion. High expression of the myogenic marker genes MYOG and MYMK can promote myotube differentiation.

[0045] sg-MYOG-Bos: 5'-GGAGCTTGGGGGCTGGTGGCAGG -3' (SEQ ID NO:3);

[0046] sg-MYMK-Bos: 5'-GCTCCACGCTCTGACTCAGCAGG-3' (SEQ ID NO:4);

[0047] sg-MYOG-Mus: 5'-TTTAAATGGCACCCAGCAGTTGG-3' (SEQ ID NO:5);

[0048] sg-MYMK-Mus: 5'-AGGAGGGCTTTAAGTGCTCTGAGG-3' (SEQ ID NO:6);

[0049] The tool provided by the present invention can achieve site-specific crotonylation modification of genes, and the tool can be used to construct a cell line edited by site-specific crotonylation modification of genes.

[0050] The present invention also provides a method for preparing gene-directed crotonylation-modified edited cells. The target cells are bovine muscle satellite cells and mouse C2C12 myoblasts, and more preferably bovine fetal muscle satellite cells. The introduction method is liposome transfection or electroporation, preferably liposome transfection, which has high transfection efficiency and little effect on cell state.

[0051] In a preferred embodiment, after the tool is introduced into the target cell, a cell line successfully transfected with the CRISPR::Cr-P300M editing vector is obtained by screening. The monoclonal editing cell screening method is a limiting dilution method. The identification method is preferably crotonyl pan-anti-ChiP-qPCR to detect the crotonyl modification level near the transcription start site of the target gene.

[0052] The cells edited by the above gene site-specific modification can be further used to detect the transcription and translation levels of the gene. Real-time fluorescence quantitative PCR is preferred for detecting the transcription level; and immunoblotting is preferred for detecting the translation level.

[0053] The main reagents used in the following examples are:

[0054] Collagenase IV used to isolate bovine fetal muscle satellite cells was purchased from Sigma;

[0055] DMEM, FBS, PBS, and Trypsase used in cell culture were purchased from Gibco;

[0056] ChiP kit was purchased from Thermo;

[0057] Primers were synthesized by Shanghai Sangon Biotechnology Co., Ltd.;

[0058] Fluorescence quantitative PCR kit was purchased from Novazon Biotech Co., Ltd.;

[0059] Antibodies used in western blotting: Antibodies against myogenic marker genes MYOG and MYMK were purchased from Abcam, and α-Tubulin antibody was purchased from Proteintech.

[0060] Main instruments:

[0061] CO2 incubator (Thermo, USA);

[0062] Fluorescence quantitative PCR instrument (Roche, Switzerland);

[0063] Exposure meter (Tanon, China).

[0064] Example 1 Construction of CRISPR::Cr-P300M crotonylation modification editing tool and cytotoxicity detection

[0065] 1.1 Synthesize a bovine P300 gene sequence, wherein the P300 protein encoded by the gene sequence has the 1395th isoleucine (I) mutated to glycine (G) ( Figure 1 ) P300 mutant, the P300 gene sequence is connected to the dCas9 sequence through the linker P2A to form a sequence that can express a fusion protein, and the dCas9-P2A-P300 mutant is connected between the T7 promoter and the hGH poly signal ( Figure 2 ).

[0066] 1.2 Based on the DNA sequences of the transcription start sites of bovine myogenic marker genes MYOG and MYMK, and the DNA sequences of the transcription start sites of mouse myogenic marker genes MYOG and MYMK ( Figure 3 ), online ( ) Design sgRNA and score it, and select sgRNA close to the transcription start site with a high score. The specific sequence is as follows:

[0067] sg-MYOG-Bos: 5'-GGAGCTTGGGGGCTGGTGGCAGG -3' (SEQ ID NO:3);

[0068] sg-MYMK-Bos: 5'-GCTCCACGCTCTGACTCAGCAGG-3' (SEQ ID NO:4);

[0069] sg-MYOG-Mus: 5'-TTTAAATGGCACCCAGCAGTTGG-3' (SEQ ID NO:5);

[0070] sg-MYMK-Mus: 5'-AGGAGGGCTTTAAGTGCTCTGAGG-3' (SEQ ID NO:6);

[0071] In order to facilitate connection with the vector backbone, linker sequences were added to the above four sgRNA sequences and complementary oligonucleotide primers were synthesized.

[0072] 1.3 Construct vectors and name them P300M-MYOG-Bos, P300M-MYMK-Bos, P300M-MYOG-Mus and P300M-MYMK-Mus respectively;

[0073] The oligonucleotide primers synthesized in step 1.2 were treated at 98°C for 10 min and then naturally cooled to room temperature for annealing.

[0074] The CRISPR::Cr-P300M vector was digested with restriction endonucleases MluI and KpnI at 37°C for 1.5 h, and the linearized fragment was recovered by gel excision.

[0075] The above annealed double-stranded fragments were mixed with the vector linear fragments and connected at 16°C overnight, transformed into DH5α competent cells, spread on LB plates containing ampicillin for growth, and then single colonies were picked for expansion and sequencing. The sequencing primers are as follows:

[0076] U6-promoter: 5'-CCGTAACTTGAAAGTATTTCG-3';

[0077] The positive clones were cultured and extracted to obtain P300M-MYOG-Bos, P300M-MYMK-Bos, P300M-MYOG-Mus and P300M-MYMK-Mus plasmids for subsequent cell transfection. Plasmid extraction was performed using a plasmid endotoxin removal kit (TIANGEN, China).

[0078] 1.4 Isolation and culture of bovine fetal muscle satellite cells (BMSCs)

[0079] The bovine muscle satellite cells used in this experiment were obtained from wild Mongolian cattle fetuses (about three months old) at the grassland livestock germplasm innovation and breeding base. The primary skeletal muscle satellite cells were isolated and cultured using the tissue adhesion method. The bovine fetal tissue was washed 3 times with PBS containing double antibodies, soaked in 75% alcohol for 5s, and quickly transferred to PBS. After washing 3 times, it was cut into 1-3 mm3 and evenly spread in a culture dish. Incubate inverted in a 38.5°C, 5% CO2 incubator for 1-2 h, and add complete culture medium after the tissue block is attached to the culture dish. When the cell growth reaches 80-90% confluence, it is subcultured and frozen.

[0080] 1.5 Culture of mouse C2C12 cells

[0081] Mouse C2C12 cells used in this experiment were purchased from Cybex Biotech Co., Ltd. C2C12 cells frozen in liquid nitrogen were quickly thawed in a 39°C water bath, and the cell suspension was centrifuged at 1500 rpm for 5 minutes. The supernatant was discarded, the cell pellet was resuspended in fresh growth medium, and inoculated into a culture dish at an appropriate density and cultured in an incubator at 37°C and 5% CO2. Cells were subcultured when they reached 80-90% confluence.

[0082] 1.6 Cell transfection

[0083] The day before transfection, primary bovine fetal muscle satellite cells or C2C12 cells were seeded into six-well plates, and transfection was performed when the cells reached 70-80% confluence. The transfection steps were strictly performed according to the instructions of the Lipofectamine 2000 (Invitrogen, USA) kit. Specifically, 6 μg of the recombinant plasmids P300M-MYOG-Bos, P300M-MYMK-Bos, P300M-MYOG-Mus, and P300M-MYMK-Mus obtained in step 1.3 were transfected into BMSCs and C2C12 cells, respectively, to obtain 8 types of transfected cells.

[0084] 1.7 Screening of edited cells by limiting dilution method

[0085] 48 h after liposome transfection, prepare the cell suspension and inoculate 96-well plates at a dilution ratio of 0.5 cells per well. After 4-5 days of culture, small cell clones can be seen, and the cells will be used for subsequent experiments after they are fully grown.

[0086] 1.8 Cell viability assay

[0087] According to the instructions of the CCK-8 (Beyotime, China) kit, the cell viability after site-directed crotonylation modification of bovine or mouse myogenic marker genes MYOG and MYMK was detected, and the OD value of the sample at 450 nm was detected using a microplate reader. Wild-type (WT) is an unedited cell, and P300 is an endogenous protein for gene site-directed editing. The results showed that the cell viability edited by site-directed crotonylation modification of bovine and mouse MYOG or MYMK did not change significantly compared with the WT group, and the cell viability after editing of endogenous P300 also did not change significantly ( Figure 4 ).

[0088] Example 2 Verification of site-directed crotonylation modification of myogenic marker genes

[0089] 2.1 ChiP-qPCR of crotonyl pan-antibody

[0090] Take 4×10 cells after editing 6 The cells were cross-linked with formaldehyde at a final concentration of 1% for 10 min.

[0091] According to the instructions of Pierce Magnetic ChIP Kit (Thermo, USA), Anti-Crotonyllysine Rabbit pAb (PTMBIO, China) was selected as the primary antibody and Rabbit IgG (CST, USA) was selected as the secondary antibody.

[0092] The immunoprecipitated DNA fragments were purified using a DNA purification kit (Beyotime, China) and used as templates for quantitative PCR (qPCR).

[0093] qPCR system: cDNA 2 μl, 1 μM upstream primer 1 μl, 1 μM downstream primer 1 μl, SYBR green master mix (TaKaRa, China) 12.5 μl and RNase-free H2O 8.5 μl, totaling 25 μl.

[0094] Reaction system: 95°C for 30 s, 95°C for 5 s, 60°C for 34 s, for a total of 40 cycles.

[0095] The primer sequences are as follows:

[0096] MYOG-Bos-1F: 5'- GGCTATATTTATCTCTGGTTC-3';

[0097] MYOG-Bos-1R: 5'-TGGAGTGGACAGGCAGGTAG -3';

[0098] MYMK-Bos-1F: 5'- TTCACACCAGCTTGGCAGGGC -3';

[0099] MYMK-Bos-1R: 5'-GGGCGACTTGCAGTGTCTGG-3';

[0100] MYOG-Mus-1F: 5'-CAGCTTAGAGGGGGGCTCAG-3';

[0101] MYOG-Mus-1R: 5'-AGAAGTGGGGCTCCTGGTAG -3';

[0102] MYMK-Mus-1F: 5'- AGAGAGAGAGAGAGAGAGAA-3';

[0103] MYMK-Mus-1R: 5'-CCCTGGTCTCCAGGGCAGG-3';

[0104] The ChiP-qPCR data were normalized using the Fold enrichment method: Foldenrichment = log2-ΔΔCt, ΔCt = Ct (IP) - Ct (Input) - log25, ΔΔCt = ΔCt –ΔCt (IgG).

[0105] The results showed that after site-specific crotonylation editing of bovine myogenic marker genes MYOG and MYMK, and after site-specific crotonylation editing of mouse myogenic marker genes MYOG and MYMK, the crotonylation level was significantly increased compared with the WT group; the crotonylation level of endogenous P300 cells after editing was also increased ( Figure 5 ).

[0106] 2.2 ChiP-qPCR of acetylated pan-antibody

[0107] Except for the use of Anti-Acetyllysine Rabbit mAb (PTMBIO, China) as the primary antibody, the other ChiP-qPCR processes were consistent with step 2.1. The results showed that after site-directed crotonylation editing of bovine myogenic marker genes MYOG and MYMK, and site-directed crotonylation editing of mouse myogenic marker genes MYOG and MYMK, the acetylation level did not change significantly compared with the WT group, and the acetylation level of endogenous P300 cells after editing was significantly increased ( Figure 6 ).

[0108] Example 3 Detection of gene transcription and protein level after site-directed crotonylation editing modification

[0109] 3.1 Real-time fluorescence quantitative PCR

[0110] Total RNA from edited cells was extracted according to the instructions of HiPuretotalRNAMiniKit (Magen, China), and the RNA concentration was measured using NanoDrop 2000 spectrophotometer (Thermo, USA).

[0111] Total RNA was reverse transcribed into cDNA using GoScriptTM Reverse Transcription Mix, Oligo(dT) (Promega, USA).

[0112] Primers were designed using Primer Premier 5.0 software. The specific sequences are as follows:

[0113] MYOG-Bos-2F: 5'- GCGCAGACTCAAGAAGGTGA-3';

[0114] MYOG-Bos-2R: 5'- TGCAGGCGCTCTATGTACTG-3';

[0115] MYMK-Bos-2F: 5'-AGTCTCCCCCATTCCTGACCC -3';

[0116] MYMK-Bos-2R: 5'-TGATGAGGGTGAACAGGACA-3';

[0117] MYOG-Mus-2F: 5'-CAGCCCAGCGAGGGAATTTA-3';

[0118] MYOG-Mus-2R: 5'- AGAAGCTCCTGAGTTTGCCC-3';

[0119] MYMK-Mus-2F: 5'-TATGGAGACAGGGGTCCA-3';

[0120] MYMK-Mus-2R: 5'-GGCATGGGAGAAACCTTTGC-3';

[0121] PCR system: 80 ng cDNA, 1 μM upstream primer, 1 μM downstream primer, SYBR green master mix (TaKaRa, China) and RNase-free H2O (20 μl in total).

[0122] Reaction system: 95°C for 30 s, 95°C for 5 s, 60°C for 34 s, for a total of 40 cycles.

[0123] GAPDH was used as an internal reference, and the primer sequences were as follows:

[0124] GAPDH-Bos-F: 5'-TGGTGAAGGTCGGAGTGAAC-3';

[0125] GAPDH-Bos-R: 5'- ATGGCGACGATGTCCACTTT-3';

[0126] GAPDH-Mus-F: 5'- CCCTTAAGAGGGATGCTGCC-3';

[0127] GAPDH-Mus-R: 5'-TACGGCCAAATCCGTTCACA-3';

[0128] The results showed that after site-specific crotonylation editing of bovine and mouse myogenic marker genes MYOG and MYMK, the mRNA expression levels of myogenic marker genes MYOG and MYMK were significantly increased ( Figure 7 ).

[0129] 3.2 Immunoblotting

[0130] The edited cells were lysed with RIPA Buffer (Beyotime, China), and the protein concentration was determined using BCA Protein Assy Kit (Beyotime, China).

[0131] Protein samples were separated by 10% SDS-PAGE and transferred to a membrane.

[0132] The primary antibody was incubated overnight at 4°C, and the secondary antibody was incubated for 1 h at 37°C. After extensive washing with 1× TBST, the membrane was exposed using an ECL chemiluminescence detection kit (Biosharp, China).

[0133] The results showed that after site-specific crotonylation editing of bovine and mouse myogenic marker genes MYOG and MYMK, MYOG ( Figure 8 ) and MYMK ( Fig. 9 ) protein expression was significantly increased.

[0134] Example 4 Myotube formation after site-directed crotonylation editing

[0135] The edited cells were induced to differentiate into myotubes and the differentiation of myotubes on the third day (D3) was observed. The results showed that after site-specific crotonylation editing of bovine myogenic marker genes MYOG and MYMK, and site-specific crotonylation editing of mouse myogenic marker genes MYOG and MYMK, BMSCs ( Fig.10 ) and C2C12 ( Fig.11 ) The myotube formation ability was significantly enhanced.

[0136] The preferred specific embodiments of the present invention are described in detail above. It should be understood that ordinary technicians in the field can make many modifications and changes based on the concept of the present invention without creative work. Therefore, all technical solutions that can be obtained by technicians in the technical field based on the concept of the present invention through logical analysis, reasoning or limited experiments on the basis of the prior art should be within the scope of protection determined by the claims.

Claims

1. A composition for site-directed crotonylation modification of CRISPR::Cr-P300M gene, characterized in that: include: A fusion protein of dCas9 and a P300 mutant and an sgRNA, wherein the amino acid sequence of the P300 mutant is shown in SEQ ID NO: 2, the sgRNA targets the transcription start site of MYMK, the MYMK is of bovine or mouse origin, and the nucleotide sequence of the sgRNA is: sg-MYMK-Bos is shown in SEQ ID NO: 4; sg-MYMK-Mus is shown as SEQ ID NO:

6.

2. The composition according to claim 1, characterized in that The dCas9 and P300 mutants were fused directly or via a linker peptide.

3. The composition according to claim 2, characterized in that The connecting peptide is P2A.

4. A CRISPR::Cr-P300M gene site-directed crotonylation modification editing vector, comprising an sgRNA expression cassette and a dCas9 and P300 mutant fusion protein expression cassette, wherein the amino acid sequence of the P300 mutant is shown in SEQ ID NO: 2, the sgRNA targets the transcription start site of bovine or mouse MYMK, and the nucleotide sequence of the sgRNA is: sg-MYMK-Bos is shown in SEQ ID NO: 4; sg-MYMK-Mus is shown as SEQ ID NO:

6.

5. Use of the composition for site-directed crotonylation modification of the CRISPR::Cr-P300M gene according to any one of claims 1 to 3 or the editing vector for site-directed crotonylation modification of the CRISPR::Cr-P300M gene according to claim 4 in the preparation of a site-directed crotonylation modified cell reagent.

6. A method for preparing cells edited by site-directed crotonylation of a non-therapeutic target gene, comprising the following steps: The composition for site-directed crotonylation modification of the CRISPR::Cr-P300M gene according to any one of claims 1 to 3 or the editing vector for site-directed crotonylation modification of the CRISPR::Cr-P300M gene according to claim 4 is introduced into the target cells to obtain cells edited with site-directed crotonylation modification of the gene.

Citation Information

Patent Citations

  • Compositions and methods of improving specificity in genomic engineering using RNA-guided endonucleases

    CN108351350A

  • RNA-guided gene editing and gene modulation

    CN114230675A

  • Compositions and methods for identifying modulators of cell type fate specialization

    CN114555805A

  • Compositions and methods for epigenome editing

    US20180023064A1